Amgen Inc. $AMGN Shares Sold by Arizona State Retirement System

Arizona State Retirement System lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 3.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 151,395 shares of the medical research company’s stock after selling 5,634 shares during the period. Arizona State Retirement System’s holdings in Amgen were worth $49,553,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. West Family Investments Inc. grew its holdings in Amgen by 1.1% during the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after purchasing an additional 30 shares in the last quarter. Viawealth LLC boosted its position in Amgen by 0.4% in the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock valued at $2,023,000 after buying an additional 30 shares during the last quarter. LOM Asset Management Ltd grew its stake in shares of Amgen by 1.2% during the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock valued at $721,000 after acquiring an additional 30 shares in the last quarter. Smith Salley Wealth Management grew its stake in shares of Amgen by 0.3% during the fourth quarter. Smith Salley Wealth Management now owns 10,786 shares of the medical research company’s stock valued at $3,530,000 after acquiring an additional 30 shares in the last quarter. Finally, Evergreen Private Wealth LLC increased its position in shares of Amgen by 4.0% during the fourth quarter. Evergreen Private Wealth LLC now owns 785 shares of the medical research company’s stock worth $257,000 after acquiring an additional 30 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $348.62 on Friday. The company has a market cap of $188.14 billion, a PE ratio of 24.50, a P/E/G ratio of 3.62 and a beta of 0.47. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29. The firm has a 50-day simple moving average of $361.24 and a 200 day simple moving average of $338.80. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter last year, the company posted $5.31 earnings per share. Amgen’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 22.18 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. Amgen’s dividend payout ratio (DPR) is 70.84%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Completed early-stage cancer study — Amgen announced completion of a Phase 1/2 MTAP‑null cancer combination study, a pipeline de‑risking milestone that could support long‑term value if follow‑up data are positive. Amgen Marks Key Milestone With Completion of Early MTAP-Null Cancer Combo Study
• Positive Sentiment: Analyst price‑target lift — Guggenheim nudged its price target to $351 (from $347) ahead of earnings, a modest endorsement that may support the stock despite the firm keeping a Neutral rating. Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings
• Neutral Sentiment: CTO retirement and leadership realignment — Amgen announced David M. Reese, M.D. will retire as EVP & Chief Technology Officer effective June 30, with a strategic leadership realignment emphasizing integration of biology and technology; operationally notable but framed as orderly. AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
• Neutral Sentiment: New/maintained Hold coverage — Bernstein and Canaccord Genuity are on Hold for AMGN (Canaccord initiated coverage with a Hold), indicating limited near‑term analyst conviction. Amgen (AMGN) Receives a Hold from Bernstein Canaccord Genuity initiates coverage of Amgen (AMGN) with hold recommendation
• Negative Sentiment: Q1 earnings expected to decline — previews from Zacks/Yahoo suggest Amgen lacks the setup for an earnings beat in the upcoming Q1 report, creating downside risk around the release. Earnings Preview: Amgen (AMGN) Q1 Earnings Expected to Decline
• Negative Sentiment: Insider selling — filings show roughly US$4.1M of insider share sales over the past year, which some investors interpret as a cautionary signal. Amgen Insiders Sell US$4.1m Of Stock, Possibly Signalling Caution

Analyst Ratings Changes

Several research analysts recently commented on the company. Guggenheim boosted their price target on Amgen from $347.00 to $351.00 and gave the stock a “neutral” rating in a research note on Thursday, April 9th. Piper Sandler raised their price objective on Amgen from $381.00 to $432.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Wells Fargo & Company lifted their price objective on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a report on Thursday, March 19th. Deutsche Bank Aktiengesellschaft upped their target price on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. Finally, TD Cowen reissued a “buy” rating on shares of Amgen in a research report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $356.62.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.